Profile data is unavailable for this security.
About the company
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.
- Revenue in USD (TTM)31.12m
- Net income in USD-77.26m
- Incorporated2012
- Employees91.00
- LocationAclaris Therapeutics Inc701 Lee Road, Suite 103WAYNE 19087United StatesUSA
- Phone+1 (484) 324-7933
- Fax+1 (302) 655-5049
- Websitehttps://www.aclaristx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Athira Pharma Inc | 0.00 | -117.67m | 85.09m | 65.00 | -- | 0.6509 | -- | -- | -3.09 | -3.09 | 0.00 | 3.41 | 0.00 | -- | -- | 0.00 | -56.25 | -30.73 | -63.93 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
| BioXcel Therapeutics Inc | 1.76m | -153.05m | 85.36m | 74.00 | -- | -- | -- | 48.61 | -5.18 | -5.18 | 0.0591 | -2.15 | 0.0134 | 0.6067 | 5.31 | 23,729.73 | -116.64 | -74.57 | -151.39 | -84.06 | 24.15 | -- | -8,715.72 | -32,300.74 | 2.49 | -15.67 | 3.47 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Jaguar Health Inc | 9.76m | -41.30m | 85.49m | 49.00 | -- | 4.58 | -- | 8.76 | -3.64 | -3.64 | 0.4239 | 0.0676 | 0.1988 | 0.2513 | 5.08 | 199,204.10 | -85.33 | -95.29 | -153.34 | -163.54 | 79.13 | 67.28 | -429.27 | -522.28 | 1.34 | -2.95 | 0.8799 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
| Personalis Inc | 73.48m | -108.30m | 85.70m | 223.00 | -- | 0.6435 | -- | 1.17 | -2.25 | -2.25 | 1.53 | 2.56 | 0.2838 | 5.80 | 4.28 | 329,511.20 | -41.83 | -28.84 | -49.51 | -34.72 | 24.78 | 28.65 | -147.38 | -96.01 | 2.89 | -- | 0.0218 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
| LifeVantage Corp | 205.45m | 3.60m | 86.36m | 248.00 | 24.32 | 3.22 | 11.87 | 0.4204 | 0.2796 | 0.2796 | 16.01 | 2.11 | 3.20 | 2.53 | 91.56 | 828,443.60 | 5.60 | 11.65 | 8.51 | 18.92 | 79.32 | 82.20 | 1.75 | 3.42 | 1.01 | -- | 0.00 | 5.23 | 3.41 | 0.9838 | -18.59 | -18.77 | -7.98 | -- |
| Aclaris Therapeutics Inc | 31.12m | -77.26m | 87.30m | 91.00 | -- | 0.6146 | -- | 2.81 | -1.09 | -1.09 | 0.4392 | 1.99 | 0.1541 | -- | 58.77 | 341,967.00 | -38.27 | -47.29 | -42.29 | -53.87 | 41.99 | 44.00 | -248.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Eton Pharmaceuticals Inc | 31.64m | -936.00k | 88.24m | 30.00 | -- | 5.70 | -- | 2.79 | -0.0389 | -0.0389 | 1.23 | 0.6025 | 1.11 | 14.42 | 12.02 | 1,054,733.00 | -3.30 | -46.22 | -5.49 | -58.20 | 66.56 | 72.16 | -2.96 | -76.86 | 1.60 | -- | 0.258 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
| Passage Bio Inc | 0.00 | -102.06m | 89.95m | 58.00 | -- | 0.7209 | -- | -- | -1.87 | -1.87 | 0.00 | 2.03 | 0.00 | -- | -- | 0.00 | -51.80 | -48.56 | -56.80 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| Milestone Pharmaceuticals Inc | 1.00m | -59.69m | 90.35m | 47.00 | -- | 3.39 | -- | 90.35 | -1.39 | -1.39 | 0.0233 | 0.5009 | 0.0134 | -- | 0.3949 | 21,276.60 | -79.73 | -48.44 | -87.55 | -51.56 | -- | -- | -5,968.50 | -1,267.25 | -- | -- | 0.748 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Chimerix Inc | 41.00k | -82.59m | 90.53m | 72.00 | -- | 0.52 | -- | 2,207.96 | -0.9296 | -0.9296 | 0.0005 | 1.94 | 0.0002 | -- | 0.1226 | 569.44 | -36.50 | -30.45 | -39.59 | -34.09 | 100.00 | -- | -201,443.90 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| Beyondspring Inc | 1.75m | -21.03m | 90.94m | 35.00 | -- | -- | -- | 51.93 | -0.5392 | -0.5392 | 0.0449 | -0.6868 | 0.0493 | -- | -- | 48,638.89 | -61.80 | -75.50 | -88.85 | -96.48 | -- | -- | -1,253.46 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -39.85m | 91.02m | 20.00 | -- | 0.7959 | -- | -- | -1.41 | -1.41 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.86 | -38.44 | -51.95 | -39.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 54.16 | -- | -- | -- |
| Spero Therapeutics Inc | 103.78m | 22.81m | 91.08m | 46.00 | 4.17 | 0.8379 | 3.92 | 0.8776 | 0.4055 | 0.4055 | 1.96 | 2.02 | 0.6757 | -- | 4.01 | 2,256,087.00 | 14.85 | -35.52 | 18.36 | -41.75 | -- | -- | 21.98 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
Data as of May 10 2024. Currency figures normalised to Aclaris Therapeutics Inc's reporting currency: US Dollar USD
53.65%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BML Capital Management LLCas of 31 Mar 2024 | 9.40m | 13.25% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 5.24m | 7.39% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 4.55m | 6.42% |
| Citadel Advisors LLCas of 31 Dec 2023 | 4.29m | 6.05% |
| Millennium Management LLCas of 05 Feb 2024 | 3.77m | 5.32% |
| Rock Springs Capital Management LPas of 31 Dec 2023 | 3.00m | 4.23% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 2.35m | 3.32% |
| D. E. Shaw & Co. LPas of 31 Dec 2023 | 1.94m | 2.73% |
| Velan Capital Investment Management LPas of 31 Dec 2023 | 1.76m | 2.48% |
| Tang Capital Management LLCas of 31 Dec 2023 | 1.75m | 2.47% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
